- Home
- BBDO vs BIIB Comparison
BBDO vs BIIB Comparison
Compare BBDO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBDO | BIIB |
|---|---|---|
| Founded | 1943 | 1978 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5B | 24.2B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | BBDO | BIIB |
|---|---|---|
| Price | $2.90 | $169.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 22 |
| Target Price | $2.55 | ★ $177.40 |
| AVG Volume (30 Days) | 59.8K | ★ 2.0M |
| Earning Date | 02-06-2026 | 10-30-2025 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | ★ 47.11 | N/A |
| EPS | 0.38 | ★ 10.97 |
| Revenue | ★ $16,507,289,161.00 | $10,065,900,000.00 |
| Revenue This Year | $78.26 | $3.61 |
| Revenue Next Year | $7.53 | N/A |
| P/E Ratio | ★ $8.11 | $15.68 |
| Revenue Growth | ★ 16.68 | 4.77 |
| 52 Week Low | $1.71 | $110.04 |
| 52 Week High | $3.31 | $185.17 |
Technical Indicators
Market Signals| Indicator | BBDO | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 48.08 |
| Support Level | $2.96 | $169.52 |
| Resistance Level | $3.08 | $175.94 |
| Average True Range (ATR) | 0.09 | 5.18 |
| MACD | -0.03 | -1.98 |
| Stochastic Oscillator | 20.00 | 12.20 |
Price Performance
Historical ComparisonAbout BBDO Banco Bradesco Sa
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).